The short version of freeze-thaw cycling fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | About 3.1 kDa | 28 residues, N-terminally acetylated |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Freely soluble in water | Also soluble in aqueous buffers |
| Storage temperature | 2 to 8 °C | Protect from light and moisture |
| Common synonyms | Thymalfasin; Tα1 | Same peptide sequence |
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
RNA interference (RNAi) is a biological process in which RNA molecules are involved in sequence-specific suppression of gene expression by double-stranded RNA, through translational or transcriptional repression. Historically, RNAi was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. The detailed study of each of these seemingly different processes elucidated that the identity of these phenomena were all actually RNAi. Andrew Fire and Craig Mello shared the 2006 Nobel Prize in Physiology or Medicine for their work on RNAi in the nematode worm Caenorhabditis elegans, which they published in 1998. Since the discovery of RNAi and its regulatory potentials, it has become evident that RNAi has immense potential in suppression of desired genes. RNAi is now known as precise, efficient, stable and better than antisense therapy for gene suppression. Antisense RNA produced intracellularly by an expression vector may be developed and find utility as novel therapeutic agents. Two types of small ribonucleic acid (RNA) molecules, microRNA (miRNA) and small interfering RNA (siRNA), are central to components to the RNAi pathway. Once mRNA is degraded, post-transcriptional silencing occurs as protein translation is prevented. Transcription can be inhibited via the pre-transcriptional silencing mechanism of RNAi, through which an enzyme complex catalyzes DNA methylation at genomic positions complementary to complexed siRNA or miRNA.
=== The supraoptic nucleus as a "model system" === The supraoptic nucleus is an important "model system" in neuroscience. There are many reasons for this: Some technical advantages of working on the supraoptic nucleus are that the cell bodies are relatively large, the cells make exceptionally large amounts of their secretory products, and the nucleus is relatively homogeneous and easy to separate from other brain regions. The gene expression and electrical activity of supraoptic neurons has been studied extensively, in many physiological and experimental conditions.
=== Independence and international reaction === The territory became nominally independent on 6 December 1977. Bophuthatswana's independence was not recognized by any government other than those of South Africa and Transkei, the first homeland to gain nominal independence. In addition, it was later internally recognized by the two additional countries within the TBVC-system, Ciskei and Venda.
== Bibliography == Schiffman MA (2010). Autologous Fat Transfer: Art, Science, and Clinical Practice. Berlin, Heidelberg: Springer. ISBN 978-3-642-00472-8. Mary White Stewart MD (2012). Silicone Spills: Breast Implants on Trial. Santa Barbara, CA: Praeger. ISBN 978-0-275-96359-0.
Sources: en.wikipedia.org
== External links == Book page on McSweeny's Archived 2013-05-14 at the Wayback Machine Dani Shapiro on Half a Life in The New York Times Book Review Strauss with Sam Tanenhaus of The New York Times Book Review Archived 2012-04-05 at the Wayback Machine Strauss and "Guilty as Not Charged" on This American Life Poets & Writers on Darin Strauss and Half a Life
List of lymphatic nodes of the human body American Society of Lymphology Glymphatic system and Meningeal lymphatic vessels - equivalent for the central nervous system Innate lymphoid cells Lymphangiogenesis Lymphangion Mononuclear phagocyte system Waldemar Olszewski – discovered fundamental processes in human tissues connected with function of the lymphatic system Trogocytosis
=== Sleepwalking and complex sleep behaviors === Zolpidem is associated with complex sleep behaviors (CSBs), defined as activities performed during sleep followed by amnesia. These activities may include walking, driving, eating, having sex, having conversations, and performing other daily activities while asleep. Research by Australia's National Prescribing Service found these activities typically occur after the first dose or within a few days of starting therapy, although they may occur at any time during treatment. Concerns regarding zolpidem-related CSBs have prompted actions by regulatory authorities, including Australia's Therapeutic Goods Administration (TGA) and the U.S. Food and Drug Administration (FDA). In February 2008, the TGA implemented a boxed warning for the drug. In April 2019, the FDA strengthened the drug's warning labeling by adding a black box warning highlighting the risk of serious injuries and fatalities related to CSBs, even at recommended doses and after single use, and added a contraindication advising against zolpidem use in patients with a history of CSBs.
10 October On the advice of Kissinger, Nixon issued secret orders to the Joint Chiefs of Staff to commence Operation Giant Lance, the sending of bombers armed with nuclear weapons toward Moscow in an effort to convince the Soviet leaders that he was not reluctant to launch a nuclear war in an effort to end the ongoing war. A squadron of 18 B-52 bombers, each carrying nuclear bombs, would be sent out on 27 October.
== Further reading == Chesnut, D. B.; Savin, A. (1999). "The Electron Localization Function (ELF) Description of the PO Bond in Phosphine Oxide". Journal of the American Chemical Society. 121 (10): 2335–2336. Bibcode:1999JAChS.121.2335C. doi:10.1021/ja984314m. Alkorta, Ibon; Sánchez-Sanz, Goar; Elguero, José; Del Bene, Janet E. (2014). "Pnicogen Bonds between X═PH3 (X = O, S, NH, CH2) and Phosphorus and Nitrogen Bases". The Journal of Physical Chemistry A. 118 (8): 1527–1537. Bibcode:2014JPCA..118.1527A. doi:10.1021/jp411623h. PMID 24547683.
Sources: en.wikipedia.org
==== Mechanism of action ==== Cannabinoid inhibits the activity of both cannabinoid receptor 1 (CBR1) and cannabinoid receptor 2 (CBR2), with a stronger inhibitory effect observed in the former. Cannabidiol also interacts with non-cannabinoid receptors, including serotonin 1A receptors. Yet, the mechanism of cannabinoid in controlling seizures is not clearly established.
=== Clinical trials === Bhatt has served as principal investigator, co-principal investigator, or steering-committee chair for multiple large, multicenter randomized controlled trials examining strategies to reduce cardiovascular events in high-risk patients. His work has included studies of sodium–glucose cotransporter2 (SGLT2) based therapies in patients with diabetes and either heart failure or chronic kidney disease, high-dose eicosapentaenoic acid (icosapent ethyl) in statin-treated patients with elevated triglycerides, intravenous antiplatelet therapy during percutaneous coronary intervention, and intensified oral antiplatelet regimens in patients with stable coronary artery disease and diabetes. His publication record includes work on standardized bleeding definitions for cardiovascular trials, stroke and acute coronary syndrome guidelines, and large outcome studies in diabetes and chronic kidney disease, many of which are highly cited and have been referenced in clinical practice discussions and educational materials in cardiology and stroke medicine.
These fractions also contained toxins readily separable from the short-chain isotoxin by preparative reverse-phase chromatography. Amino-acid sequencing of the first 28 residues indicated that both toxins were long-chain neurotoxins with identical N-termini. The LD50 of long-chain neurotoxins 2 from N. a. annulata and N. christyi venoms were 0.086 and 0.090 mg/kg, respectively. The venoms of these little-known elapids have some of the lowest intraperitoneal LD50 values of any African Naja species studied thus far, and have high concentrations of potent postsynaptic neurotoxins.
An UP element upstream of the rrn P1 promoter can bind a subunit of RNA polymerase, thus promoting transcription of rRNA. Transcription factors such as FIS bind upstream of the promoter and interact with RNA polymerase which facilitates transcription. Anti-termination factors bind downstream of the rrn P2 promoter, preventing premature transcription termination. Due to the stringent response, when the availability of amino acids is low, ppGpp (a negative effector) can inhibit transcription from both the P1 and P2 promoters.
Sources: en.wikipedia.org
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.
The name traces back to thymosin fraction 5, a crude thymus extract examined in the 1970s. Individual peptides in that mixture were labeled with Greek letters, and alpha-1 was one of them. The international nonproprietary name thymalfasin was assigned later.
No. Thymosin beta-4 contains 43 residues and binds actin, while thymosin alpha-1 contains 28 residues and acts on immune cells. The two sit in a historical naming group but share no sequence similarity, and they are not substitutes for one another.
Thymosin fraction 5 is a mixture of many peptides obtained from thymus tissue, while thymosin alpha 1 is a single defined 28-residue molecule. The two names appear together in older literature because the purified peptide was first obtained from that mixture.